{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-042737","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.179857+00:00","generated_at":"2026-06-14T15:56:00.329285+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Adial receives Nasdaq deficiency letter for stockholders' equity shortfall","bullets":["On May 19, 2023, Nasdaq notified Adial that stockholders' equity of $1,439,848 as of March 31, 2023 was below the $2.5M minimum.","Company has until July 3, 2023 to submit a compliance plan; if accepted, may receive up to 180-day extension.","Adial remains under a separate minimum bid price deficiency with a compliance deadline of August 28, 2023.","Management is evaluating options including a reverse stock split to regain compliance with both Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-042737","json":"https://secwatch.observer/filing/0001213900-23-042737.json","markdown":"https://secwatch.observer/filing/0001213900-23-042737.md","text":"https://secwatch.observer/filing/0001213900-23-042737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023042737/0001213900-23-042737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023042737/ea179159-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:56:00.329285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d480f60273191f13f1d82cd5589cc11020ca260","claim":"ADIAL PHARMACEUTICALS, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 19, 2023, Adial Pharmaceuticals, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $1,439,848 as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued o","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023042737/0001213900-23-042737-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}